Regeneron Investors Can't Use FCA Action To Support Suit
Regeneron Pharmaceuticals Inc. and its executives have beaten a proposed class action accusing them of misleading investors about the company's revenue prospects for its vision loss drug and inflating reimbursements, with...To view the full article, register now.
Already a subscriber? Click here to view full article